Immunohistochemistry (IHC) is the routine pathological technique used to evaluate hormone receptor (HR) status, HER2 expression, among other markers to better stratify BC subtypes.1, 2Immunohistochemistry performed in the diagnostic preoperative core needle biopsy (CNB) samples is critical to define whether neoadjuvant therapy is necessary and the type of drug regimen to be used.3, 4In case of pathologic complete response, which is common in more aggressive BC subtypes after neoadjuvant treatment, the CNB specimen can be the only biological material left for further biomarkers analysis. The gene discussed is NR4A1; the disease is breast cancer.